Tri- and Difluoromethylated Spiro[5.5]trienones Inhibit the Growth of Cancer Cells In Vitro and In Vivo

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Cancer is a leading global cause of death, necessitating improved treatments.
• Novel therapeutic agents are urgently needed to combat cancer.
• This study focuses on novel fluorinated spiro[5.5]trienone compounds.

Purpose of the Study:

• To synthesize and investigate the anticancer properties of new tri- and difluoromethylated spiro[5.5]trienones.
• To evaluate the antitumor efficacy and mechanism of action of a lead compound, designated 3s.
• To assess the in vivo efficacy and toxicity of compound 3s in a preclinical model.

Main Methods:

• Methyl thiazolyl tetrazolium (MTT) assay for cell growth inhibition.
• Flow cytometry for cell cycle analysis and reactive oxygen species (ROS) measurement.
• Western blot for protein expression analysis and in vivo mouse xenograft model for antitumor efficacy and toxicity assessment.

Main Results:

• All 21 synthesized compounds inhibited cancer cell growth.
• Compound 3s exhibited the most potent inhibitory effect, inducing G2/M cell cycle arrest and apoptosis.
• 3s activated JNK and ERK signaling pathways and increased intracellular ROS levels.
• In vivo studies showed significant tumor growth inhibition by 3s with minimal toxicity.

Conclusions:

• Compound 3s displays significant in vitro and in vivo anticancer activity.
• 3s demonstrates a promising profile for development as a novel cancer therapeutic.
• The findings suggest 3s as a potential candidate for future cancer therapy strategies.